Nursing analysis of antiemetic effect of epirubicin combined with cyclophosphamide chemotherapy in breast cancer patients in tumor day ward
乳腺癌患者使用表柔比星联合环磷酰胺化疗的止吐方案联合饮食指导的护理分析

摘要

目的 探究乳腺癌患者使用表柔比星联合环磷酰胺化疗的止吐方案联合饮食指导的护理分析。方法2022年7月至2023年3月期间本科室收治的乳腺癌患者使用表柔比星联合环磷酰胺的化疗方案中抽取52例，分为对照组和试验组，每组各26例，对照组给予福沙匹坦双葡甲胺+甲磺酸多拉司琼+地塞米松+化疗后饮食指导，试验组：对照组的地塞米松改为阿瑞匹坦胶囊，化疗后饮食指导改为化疗前后饮食指导，比较两组患者化疗后出现恶心呕吐的时间、出现恶心呕吐的分级。结果 对照组患者第一天出现恶心呕吐1级的比例为38.46%，出现2级的比例为11.54%；试验组患者第一天出现恶心呕吐1级的比例为7.69%，出现2级的比例为0.00%，差异有统计学意义（P<0.05）。对照组患者第二天出现恶心呕吐1级的比例为15.38%，出现2级的比例为11.54%；试验组患者第二天出现恶心呕吐1级比例例为19.23%，出现2级的比例为7.69%，差异有统计学意义（P<0.05）。两组患者化疗后研究组恶心呕吐1级及1级以上的患者明显少于对照组（P＜0.05）。结论 福沙匹坦双葡甲胺+阿瑞匹坦胶囊+甲磺酸多拉司琼+化疗前后饮食指导，在乳腺癌患者使用表柔比星联合环磷酰胺化疗中改善患者的恶心呕吐效果显著。

Abstract

Objective To explore the nursing analysis of epirubicin and cyclophosphamide chemotherapy in breast cancer patients.
Methods during July 2022 to March 2023 of breast cancer patients using epirubicin combined with cyclophosphamide chemotherapy in 52 cases, divided into control group and test group, each group 26 cases, control group + dolazone + dexamethasone + diet instruction, test group: control group of dexamethasone to aspirin capsule, diet guidance after chemotherapy, compare the time of nausea and vomiting after chemotherapy, nausea and vomiting grade.
Results In the control group, 38.46% experienced grade 1 and 11.54%, there were 7.69% and 0.00%, with a statistically significant difference (P <0.05). In the control group, 15.38% of the patients and grade 2 were 11.54%, 19.23% on the next day, and grade 2 was 7.69%, with a significant difference (P <0.05). Patients in the study groups had significantly less nausea and vomiting grade 1 and above than those in the control group (P <0.05).
Conclusion   Betammethine + Relitan capsule + dolasetron mesylate + dietary guidance before and after chemotherapy to improve nausea and vomiting in breast cancer patients with epirubicin combined with cyclophosphamide chemotherapy.